These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 36147706)

  • 1. Treatment with sotrovimab for SARS-CoV-2 infection in a cohort of high-risk kidney transplant recipients.
    Villanego F; Mazuecos A; Cubillo B; Merino MJ; Poveda I; Saura IM; Segurado Ó; Cruzado L; Eady M; Zárraga S; Aladrén MJ; Cabello S; López V; González E; Lorenzo I; Espí-Reig J; Fernández C; Osma J; Ruiz-Fuentes MC; Toapanta N; Franco A; Burballa CC; Muñoz MA; Crespo M; Pascual J
    Clin Kidney J; 2022 Oct; 15(10):1847-1855. PubMed ID: 36147706
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of bebtelovimab and sotrovimab treatment of solid organ transplant recipients with mild-to-moderate coronavirus disease 2019 during the Omicron epoch.
    Yetmar ZA; Beam E; O'Horo JC; Seville MT; Brumble L; Ganesh R; Razonable RR
    Transpl Infect Dis; 2022 Aug; 24(4):e13901. PubMed ID: 35848574
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.
    Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Rodrigues Falci D; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Parra S; Sager JE; Austin D; Peppercorn A; Alexander E; Yeh WW; Brinson C; Aldinger M; Shapiro AE;
    JAMA; 2022 Apr; 327(13):1236-1246. PubMed ID: 35285853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series.
    Fernandes G; Devresse A; Scohy A; De Greef J; Yombi JC; Belkhir L; Darius T; Mourad M; Buemi A; Kabamba B; Goffin E; Kanaan N
    Kidney Med; 2022 Jun; 4(6):100470. PubMed ID: 35493029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Vaccination and Early Monoclonal Antibody Therapy on Coronavirus Disease 2019 Outcomes in Organ Transplant Recipients During the Omicron Wave.
    Solera JT; Árbol BG; Alshahrani A; Bahinskaya I; Marks N; Humar A; Kumar D
    Clin Infect Dis; 2022 Dec; 75(12):2193-2200. PubMed ID: 35445690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Use of Sotrovimab in Children: A Case Report of an 11-Year-Old Kidney Transplant Recipient Infected with SARS-CoV-2.
    Di Chiara C; Mengato D; De Pieri M; Longo G; Benetti E; Venturini F; Giaquinto C; Donà D
    Children (Basel); 2022 Mar; 9(4):. PubMed ID: 35455495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotrovimab in Hospitalized Patients with SARS-CoV-2 Omicron Variant Infection: a Propensity Score-Matched Retrospective Cohort Study.
    Woo MS; Brehm TT; Fischer M; Heyer A; Wichmann D; Jordan S; Nörz D; Lütgehetmann M; Addo MM; Lohse AW; Schmiedel S; Kluge S; Schulze Zur Wiesch J
    Microbiol Spectr; 2023 Feb; 11(1):e0410322. PubMed ID: 36475890
    [No Abstract]   [Full Text] [Related]  

  • 8. Real-World Effectiveness of Sotrovimab for the Early Treatment of COVID-19 During SARS-CoV-2 Delta and Omicron Waves in the USA.
    Cheng MM; Reyes C; Satram S; Birch H; Gibbons DC; Drysdale M; Bell CF; Suyundikov A; Ding X; Maher MC; Yeh W; Telenti A; Corey L
    Infect Dis Ther; 2023 Feb; 12(2):607-621. PubMed ID: 36629998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19 Infection With the Omicron SARS-CoV-2 Variant in a Cohort of Kidney and Kidney Pancreas Transplant Recipients: Clinical Features, Risk Factors, and Outcomes.
    Wong G; Rowlandson M; Sabanayagam D; Ginn AN; Kable K; Sciberras F; Au E; Draper J; Arnott A; Sintchenko V; Dwyer DE; Chen SCA; Kok J
    Transplantation; 2022 Sep; 106(9):1860-1866. PubMed ID: 35675438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients.
    Aggarwal NR; Beaty LE; Bennett TD; Carlson NE; Davis CB; Kwan BM; Mayer DA; Ong TC; Russell S; Steele J; Wogu AF; Wynia MK; Zane RD; Ginde AA
    J Infect Dis; 2022 Dec; 226(12):2129-2136. PubMed ID: 35576581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What Is the Efficacy of Sotrovimab in Reducing Disease Progression and Death in People with COVID-19 during the Omicron Era? Answers from a Real-Life Study.
    De Vito A; Colpani A; Poliseno M; Diella L; Ieva FRP; Belati A; Papale R; Babudieri S; De Santis L; Saracino A; Lo Caputo S; Madeddu G
    Viruses; 2023 Aug; 15(8):. PubMed ID: 37632099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curbing the Delta Surge: Clinical Outcomes After Treatment With Bamlanivimab-Etesevimab, Casirivimab-Imdevimab, or Sotrovimab for Mild to Moderate Coronavirus Disease 2019.
    Razonable RR; O'Horo JC; Challener DW; Arndt L; Arndt RF; Clune CG; Culbertson TL; Hall ST; Heyliger A; Jackson TA; Kennedy BD; Larsen J; Hanson SN; Sweeten PW; Tulledge-Scheitel SM; Ganesh R
    Mayo Clin Proc; 2022 Sep; 97(9):1641-1648. PubMed ID: 36058578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.
    Gupta A; Gonzalez-Rojas Y; Juarez E; Crespo Casal M; Moya J; Falci DR; Sarkis E; Solis J; Zheng H; Scott N; Cathcart AL; Hebner CM; Sager J; Mogalian E; Tipple C; Peppercorn A; Alexander E; Pang PS; Free A; Brinson C; Aldinger M; Shapiro AE;
    N Engl J Med; 2021 Nov; 385(21):1941-1950. PubMed ID: 34706189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world effectiveness of sotrovimab in preventing hospitalization and mortality in high-risk patients with COVID-19 in the United States: A cohort study from the Mayo Clinic electronic health records.
    Bell CF; Gibbons DC; Drysdale M; Birch HJ; Lloyd EJ; Patel V; Carpenter C; Carlson K; Calay ES; Puranik A; Wagner TE; O'Horo JC; Razonable RR
    PLoS One; 2024; 19(7):e0304822. PubMed ID: 39012863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial.
    ACTIV-3/Therapeutics for Inpatients with COVID-19 (TICO) Study Group
    Lancet Infect Dis; 2022 May; 22(5):622-635. PubMed ID: 34953520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Outcomes of Sotrovimab Treatment in 10 High-Risk Patients with Mild COVID-19: A Case Series.
    Takeda K; Kasai H; Sakao S; Saito M; Shikano K; Naito A; Abe M; Kawasaki T; Yahaba M; Taniguchi T; Igari H; Suzuki T
    Am J Case Rep; 2022 Jul; 23():e936832. PubMed ID: 35802524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and tolerability study of sotrovimab (VIR-7831) prophylaxis against COVID-19 infection in immunocompromised individuals with impaired SARS-CoV-2 humoral immunity.
    Gonzalez-Bocco IH; Beluch K; Cho A; Lahoud C; Reyes FA; Moshovitis DG; Unger-Mochrie GM; Wang W; Hammond SP; Manne-Goehler J; Koo S
    Pilot Feasibility Stud; 2023 Jun; 9(1):100. PubMed ID: 37328890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sotrovimab in solid organ transplant recipients with COVID-19: a systematic review and meta-analysis.
    Amani B; Shabestan R; Rajabkhah K; Amani B
    Korean J Transplant; 2023 Dec; 37(4):277-285. PubMed ID: 37916433
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Comparison of the Adverse Effects and Utility of Different Monoclonal Antibodies for SARS-CoV-2: A Retrospective Cohort Study.
    Knopp BW; Weiss HZ; Fahmy S; Goldstein E; Parmar J
    Cureus; 2023 Aug; 15(8):e43094. PubMed ID: 37680398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.